Fig 1.

(A) Overall survival (OS) of the post–external-beam radiation therapy (XRT) patients was superior to that of the post–cytotoxic chemotherapy/combined-modality therapy (C/CMT) patients (P = .006), but was not significantly different from that of the de novo patients (P = .8). (B) OS of patients with myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) after XRT was superior to that of patients after C/CMT (P < .001), but was not significantly different from that of patients with de novo MDS/CMML (P = .9). (C) For patients diagnosed with acute myeloid leukemia (either on presentation or as progression from prior MDS), OS of post-XRT patients was superior to that of post-C/CMT patients (P = .03) but was not different from that of de novo patients (P = .8).